Leap Therapeutics, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Douglas E. Onsi
- Full Time Employees
- 52
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 47 Thorndike Street Cambridge MA United States of America 02141
- IPO Date
- Jan 25, 2017
- CIK
- 0001509745
- Website
- leaptx.com
- Similar Companies
- Business
- Leap Therapeutics, Inc. (Nasdaq: LPTX) is a clinical-stage biopharmaceutical company that acquires, develops, and commercializes targeted antibody therapies for cancer patients; its lead product candidate, sirexatamab (DKN-01), comprises a humanized monoclonal antibody inhibiting Dickkopf-1 (DKK1) protein in advanced esophagogastric, gynecologic, endometrial, gastric, and colorectal cancers, including ongoing or completed trials combining sirexatamab with tislelizumab plus chemotherapy, bevacizumab plus chemotherapy, or pembrolizumab; FL-301 offers a humanized monoclonal antibody targeting Claudin18.2 for gastric and pancreatic cancers; and FL-501 provides a humanized monoclonal antibody inhibiting growth and differentiation factor 15 (GDF-15) protein in preclinical development. The company maintains license and option agreements with Adimab, LLC, and BeiGene, Ltd., for DKN-01 development and commercialization in Asia (excluding Japan), Australia, and New Zealand. Founded in 2011 and headquartered in Cambridge, Massachusetts, Leap Therapeutics operates primarily in the United States with a global clinical trial footprint targeting oncology patients expressing specific biomarkers. Recent developments include the July 2025 acquisition of Flame Biosciences for approximately $50 million in cash and stock to expand its Claudin18.2 pipeline with FL-301; a June 2025 strategic restructuring with 50-75% workforce reduction, positive Phase 2 DeFianCe trial data for sirexatamab in colorectal cancer, and exploration of alternatives such as partnerships or sales advised by Raymond James; and a $58.9 million private placement in October 2025 led by Winklevoss Capital to fund digital asset treasury initiatives, FL-501 advancement, and sirexatamab programs, alongside board expansion and Winklevoss nominees including a chair.
Leap Therapeutics (NASDAQ:LPTX) vs. Panbela Therapeutics (OTCMKTS:PBLA) Head-To-Head Analysis
Leap Therapeutics (NASDAQ:LPTX) and Nemus Bioscience (OTCMKTS:NMUS) Critical Contrast
Contrasting Leap Therapeutics (NASDAQ:LPTX) and UCB (OTCMKTS:UCBJF)
Reviewing Leap Therapeutics (NASDAQ:LPTX) and Vincerx Pharma (NASDAQ:VINC)
Analyzing PaxMedica (NASDAQ:PXMD) and Leap Therapeutics (NASDAQ:LPTX)
Cypherpunk Technologies (formerly Leap Therapeutics) Reports Third Quarter 2025 Financial Results
Leap Therapeutics Rebrands as Cypherpunk; Expands Leadership Team to Drive New Zcash Treasury Strategy
Leap Therapeutics Presents Final Data from DeFianCe Study at ESMO 2025
Leap Therapeutics Announces Closing of $58.88 Million Private Placement in Cash Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy
Leap Therapeutics Announces $58.88 Million Private Placement in Cash Commitments Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy
Leap Therapeutics to Present Final Clinical Data from Part B of the DeFianCe Study at the ESMO Congress 2025
Leap Therapeutics Reports Second Quarter 2025 Financial Results
Leap Therapeutics Reports Updated Clinical Data from Sirexatamab Colorectal Cancer Study and Announces Exploration of Strategic Alternatives
Leap Therapeutics Reports First Quarter 2025 Financial Results
Leap Therapeutics to Present Preclinical Data of FL-501, a Novel GDF-15 Neutralizing Antibody, at the AACR 2025 Annual Meeting
Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal Cancer
Leap Therapeutics (LPTX) Conference Call to discuss Updated Data from Part B of the DeFianCe Study Transcript
Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer
Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study